The stock of Vertex Pharmaceuticals, Inc (VRTX) has gone down by -10.62% for the week, with a -5.18% drop in the past month and a -6.69% drop in the past quarter. The volatility ratio for the week is 3.50%, and the volatility levels for the past 30 days are 3.50% for VRTX. The simple moving average for the past 20 days is -8.08% for VRTX’s stock, with a -4.53% simple moving average for the past 200 days.
Is It Worth Investing in Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) Right Now?
VRTX has 36-month beta value of 0.48. Analysts have mixed views on the stock, with 16 analysts rating it as a “buy,” 4 as “overweight,” 13 as “hold,” and 1 as “sell.”
The public float for VRTX is 256.33M, and currently, short sellers hold a 1.71% ratio of that float. The average trading volume of VRTX on May 07, 2025 was 1.48M shares.
VRTX) stock’s latest price update
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX)’s stock price has decreased by -10.03 compared to its previous closing price of 500.19. However, the company has seen a -10.62% decrease in its stock price over the last five trading sessions. seekingalpha.com reported 2025-05-06 that Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex’s diversification efforts are most visible in the progress of its pain management portfolio. The FDA approval of Journavx marks the beginning of a new era for the company. VRTX is not going to be the same company by 2030. I expect notable changes in its margin profile as the company diversifies into new markets.
Analysts’ Opinion of VRTX
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see VRTX reach a price target of $535. The rating they have provided for VRTX stocks is “Overweight” according to the report published on April 22nd, 2025.
Canaccord Genuity gave a rating of “Hold” to VRTX, setting the target price at $424 in the report published on February 12th of the current year.
VRTX Trading at -8.48% from the 50-Day Moving Average
After a stumble in the market that brought VRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.44% of loss for the given period.
Volatility was left at 3.50%, however, over the last 30 days, the volatility rate increased by 3.50%, as shares sank -5.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.56% lower at present.
During the last 5 trading sessions, VRTX fell by -10.62%, which changed the moving average for the period of 200-days by -7.80% in comparison to the 20-day moving average, which settled at $489.61. In addition, Vertex Pharmaceuticals, Inc saw 11.75% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRTX starting from Bhatia Sangeeta N., who sale 400 shares at the price of $505.86 back on May 02 ’25. After this action, Bhatia Sangeeta N. now owns 4,831 shares of Vertex Pharmaceuticals, Inc, valued at $202,344 using the latest closing price.
Bhatia Sangeeta N., the Director of Vertex Pharmaceuticals, Inc, proposed sale 400 shares at $505.86 during a trade that took place back on May 02 ’25, which means that Bhatia Sangeeta N. is holding shares at $202,344 based on the most recent closing price.
Stock Fundamentals for VRTX
Current profitability levels for the company are sitting at:
- -0.07 for the present operating margin
- 0.86 for the gross margin
The net margin for Vertex Pharmaceuticals, Inc stands at -0.09. The total capital return value is set at -0.04. Equity return is now at value -5.64, with -4.23 for asset returns.
Based on Vertex Pharmaceuticals, Inc (VRTX), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -0.3. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -43.76.
Currently, EBITDA for the company is 484.9 million with net debt to EBITDA at -7.23. When we switch over and look at the enterprise to sales, we see a ratio of 10.58. The receivables turnover for the company is 6.14for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.65.
Conclusion
To put it simply, Vertex Pharmaceuticals, Inc (VRTX) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
